Obesity最新文献

Robino, JJ, Plekhanov, AP, Zhu, Q, Jensen, MD, Scherer, PE, Roberts, CT, Varlamov, O. Adipose tissue analysis toolkit (ATAT) for automated analysis of adipocyte size and extracellular matrix in white adipose tissue. Obesity. 2024; 32(4): 723–732. doi:10.1002/oby.23992

On page 732, the Funding Information provided for this article was incorrect.

“This study was supported by National Institutes of Health grants R01AI142841, R01DK122843, R01AG071441, 1S10OD025002-01, P51OD01192, and P50HD071836 for operation of the Oregon National Primate Research Center.”

It should be corrected as follows:

“This study was supported by National Institutes of Health grants R01AI142841, R01DK122843, R01AG071441, 1S10OD025002-01, P50HD071836, and P51OD01192 for operation of the Oregon National Primate Research Center.”

The online version of the article has been corrected accordingly.

We apologize for this error.

Targeting the cannabinoid type 1 receptor (CB1) is a clinically validated antiobesity therapeutic approach. The only such drug approved, rimonabant, was launched in 2006 in Europe but subsequently rejected by the US Food and Drug Administration (FDA) in 2007. The FDA cited the increased risk of suicidality in its opposition to rimonabant's approval, leading to the drug's eventual worldwide withdrawal and the abandonment of this class of therapeutics. Seventeen years later, a new class of CB1-targeting drugs is emerging, but the impact of the 2007 FDA decision remains a formidable obstacle to its clinical development. We revisit the suicidality data presented by the FDA in light of the evolution of suicidality assessment and cross-reference this with the data in the subsequently published clinical trials. We conclude that the publicly available data do not support the FDA's conclusion that the use of rimonabant was associated with an increase in the risk of suicidality.

The improved efficacy and generally favorable safety profile of recently approved and emerging antiobesity medications (AOMs), which result in an average weight reduction of ≥15%, represent significant advancement in the treatment of obesity. This narrative review aims to provide practical evidence-based recommendations for nutritional assessment, management, and monitoring of patients treated with AOMs. Prior to treatment, clinicians can identify preexisting nutritional risk factors and counsel their patients on recommended intakes of protein, dietary fiber, micronutrients, and fluids. During treatment with AOMs, ongoing monitoring can facilitate early recognition and management of gastrointestinal symptoms or inadequate nutrient or fluid intake. Attention should also be paid to other factors that can impact response to treatment and quality of life, such as physical activity and social and emotional health. In the context of treatment with AOMs, clinicians can play an active role in supporting their patients with obesity to improve their health and well-being and promote optimal nutritional and medical outcomes.

Moran LJ, Lee J-K, Jones D, Fronberg K, Feinberg ME. Coparenting-focused preventive intervention reduces postnatal maternal BMI and buffers impact of cortisol. Obesity. 2022;30(8):1564–1572. doi:10.1002/oby.23466

On page 1569, in the first paragraph of the “Discussion” section, the text “We also found that randomization to the coparenting intervention eliminated the inverse association of change in maternal cortisol with change in maternal BMI observed in the control group” was incorrect.

This should have read as follows:

“We also found that randomization to the coparenting intervention eliminated the association of change in maternal cortisol with change in maternal BMI observed in the control group.”

We apologize for this error.